December 2025
Eosinophilic Esophagitis: A Primary Care Guide to Recognition and Management
Faculty: Mirna Chehade, MD, MPH, and Joel J. Heidelbaugh, MD; Medical Writer: Tenneisa Jackson, MBBS
Learning Objectives
• Explain the role of type 2 inflammation in the disease development and treatment considerations for eosinophilic esophagitis (EoE).
• Assess signs and symptoms of EoE that should prompt further clinical investigation.
• Apply evidence-based strategies to efficiently identify EoE in affected patients.
• Summarize strategies for optimizing referrals and follow-up care management in primary care for patients with EoE.
Activity Disclosures
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Projects In Knowledge® adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests)*. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Mirna Chehade, MD, MPH, has received consulting fees from Adare Pharma Solutions/Ellodi Pharmaceuticals, Allakos Inc., Apogee Therapeutics, AstraZeneca, Bristol Myers Squibb, Nexstone Immunology/Uniquity Bio, Phathom Pharmaceuticals, Recludix Pharma, Regeneron Pharmaceuticals, Inc., Sanofi, and Shire/Takeda; and has received research funding from Adare Pharma Solutions/Ellodi Pharmaceuticals, Allakos Inc., AstraZeneca, Celgene, Danone, Regeneron Pharmaceuticals, Inc., and Shire/Takeda.
Joel J. Heidelbaugh, MD, has no relevant financial relationships to disclose.
Tenneisa Jackson, MBBS (medical writer) has no relevant financial relationships to disclose.
Projects In Knowledge staff members have no relevant financial relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
*An ineligible company (commercial interest) is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used, on patients.
Off-Label Drug Statement: This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Accreditation
In support of improving patient care, this activity has been planned and implemented by Projects In Knowledge and John Wiley and Sons, Inc. Projects In Knowledge is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
Projects In Knowledge designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Projects In Knowledge has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 Credit(s)™. Approval is valid until 12/30/2026. PAs should only claim credit commensurate with the extent of their participation.
Upon completion of this course, participants will be awarded 0.50 nursing contact hour(s). Joint Accreditation Nursing Provider Number: 4008235
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 0.50 contact hour(s)(0.05 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is JA4008235-0000-25-252-H01-P
To begin, please click the Pre-test button below to test your understanding of the subject.
